Dihexa
A modified hexapeptide angiotensin IV analog reported in animal studies to be far more potent than BDNF at promoting new synapse formation.
Overview
Dihexa is a synthetic hexapeptide (N-hexanoic-Tyr-Ile-(6) aminohexanoic amide) that acts as an angiotensin IV analog. Animal research suggested it could form new functional synapses with potency far exceeding BDNF, attracting biohacker and nootropic interest. Human safety and efficacy data remain extremely limited.
Benefits
- Reported to support neurogenesis and synaptogenesis
- May enhance memory and learning in animal models
- Orally bioavailable
- Studied for neurodegenerative disease applications
Mechanism of Action
Acts on the hepatocyte growth factor (HGF/c-Met) receptor system, promoting synapse formation and neurogenesis through pathways related to BDNF signaling.
Dosage (informational only)
- Typical range
- 8–45 mg per day in research protocols
- Frequency
- Once or twice daily
Human safety data is extremely limited. Most evidence comes from rodent studies.
Side Effects
- Limited human data
- Possible headache
- Theoretical risk of unwanted tissue growth from HGF activation
Related peptides
A synthetic ACTH-derived peptide developed in Russia and widely studied for cognitive enhancement and stroke recovery.
A synthetic peptide modeled on tuftsin, used in Russia for anxiety and cognitive enhancement without the sedation of typical anxiolytics.
A long-acting GLP-1 receptor agonist studied for its effects on appetite, satiety, and glucose regulation.